DRD3抗体;DRD3 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12557(DRD3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The dopamine D3 receptor (DRD3) is a G protein-coupled receptor (GPCR) primarily expressed in the mesolimbic pathway of the central nervous system, including regions like the nucleus accumbens and islands of Calleja. It belongs to the D2-like receptor subfamily, sharing structural and functional similarities with DRD2 but exhibiting higher affinity for dopamine. DRD3 is implicated in regulating emotional behavior, cognition, and reward mechanisms, with dysregulation linked to neuropsychiatric disorders such as schizophrenia, Parkinson’s disease, and addiction. Its role in modulating dopamine signaling—via inhibition of adenylate cyclase and activation of MAPK/AKT pathways—makes it a therapeutic target for antipsychotics and anti-addiction drugs.

DRD3 antibodies are essential tools for studying receptor localization, expression levels, and signaling mechanisms in both normal and pathological conditions. These antibodies are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to visualize DRD3 distribution in tissues or quantify its expression in disease models. Specificity validation is critical due to high homology between DRD2 and DRD3. Commercially available antibodies often target unique epitopes in extracellular or intracellular domains. Recent research focuses on DRD3's involvement in drug-seeking behaviors and its potential as a biomarker or therapeutic target. However, challenges remain in developing selective agonists/antagonists and understanding its complex interactions with other dopamine receptors.